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U.S. adults with end-stage renal disease. The Medical Expenditure Panel Survey, a 
representative sample of the U.S. households was utilized. End-stage renal disease 
cases with clinical classification codex value of 158 were pooled for calendar cyears 
2002 to 2011. Self-reported body mass index was classified as underweight (BMI < 
18.5), normal weight (18.50 < BMI < 24.99), overweight (25 < BMI < 29.99) and obese 
(BMI > 30). Mean annual health care use and expenditures were estimated by body 
mass index among end-stage renal disease adults. RESULTS: 1.9% of end-stager 
renal disease adults were underweight (exluded due to small sample size), 28.0% 
were normal weight, 39.0% were overweight and 31% were obese. Mean annual non-
zero hospital night stays were 25, 2, and 20 days for normal weight, overweight and 
obese end-stage renal adults. The average annual expenditures were $21672 + $4903, 
$44810 + $25906, and $71992 + 41046 among normal weight, overweight and obese 
end-stage renal disease adults. CONCLUSIONS: Obese patients had longer hospital 
stays than overweight patients and resulted in higher health care expenditures. 
End-stage renal disease patients who were obese may be more sicker. With the 
rising incidence of chronic kidney disease, overweight and obesity internationally, 
the relationship of body weight with chronic kidney disease in health care use and 
associated spending needs further exploration in larger studies.
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OBJECTIVES: Healthcare costs in the U.S. are the highest worldwide and are rapidly 
increasing. As a result of this upward trend, employers and health insurance com-
panies are trying to contain the cost of healthcare. This study aimed to understand 
and identify several factors associated with medical reimbursement amount for 
Commercial and Medicare health insurance members in Southeastern Pennsylvania 
and surrounding counties. METHODS: Using privately insured Commercial and 
Medicare health plan enrollment and claims data from 2011 and 2012 for 2 mil-
lion participants, this study empirically examined the impact of socio-demographic, 
enrollment, census data, rate relativity, utilization, risk scores and chronic diseases 
on medical reimbursement amount using risk adjustment and risk predictive models. 
The dependent variables - medical reimbursement amount, was measured separately 
as concurrent, prospective, and change variable (taking first difference) at each plan 
participant level. Regression analysis was used to examine individually and cumu-
latively how much variation was explained by different independent variables for 
Commercial and Medicare separately using adjusted R-squared. Socio-demographic 
variables included age, gender, and derived 2010 census variables at the ZIP code 
level. Separate risk scores were derived for Commercial and Medicare using DxCG’s 
all medical predicting concurrent medical risk. RESULTS: Among both Commercial 
and Medicare members, utilization (including services by inpatient, outpatient and 
professional) was the predominant predictor of medical reimbursement amount. Risk 
scores and number of chronic diseases are predictive but not as significant as utiliza-
tion in terms of explanatory power. Socio-demographic variables are important pre-
dictors but only explain a small portion of the variation. CONCLUSIONS: This study 
examined several factors associated with medical reimbursement amount. Further 
research is needed to help understand what other factors are important which may 
help shed light on potential options for ‘bending the cost curve’.
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OBJECTIVES: To describe out-of-pocket (OOP) expenditures for hospitalizations, 
ambulatory care visits and prescription medications and to determine if there is the 
difference in OOP expenditures by insurance status among subjects with Chronic 
Obstructive Pulmonary Disease (COPD). METHODS: Data for this study were drawn 
from the 2012 Medical Expenditure Panel Survey (MEPS). The sample included adults 
(≥ 18 years) with a COPD diagnosis (ICD-9 codes 491, 492, and 496) who received COPD 
services at least once in 2012. The dependent variable was annual OOP expenditures 
and the independent variable was health insurance type (private, public, or no insur-
ance). Descriptive statistics and inferential tests were conducted using SAS ProcSurvey 
for complex sampling design. RESULTS: Study subjects’ (N= 587 unweighted; 
N= 5,982,925 weighted) total mean±SE OOP COPD expenditures were $236.2±45.1 per 
person. Subjects with no insurance had total OOP expenditures ($621.3±385.9) that 
were 2.8 to 4.0 times higher than those who were privately ($221.4±22.6) or publicly 
($156.9±22.9) insured. Inpatient expenditures (N= 31 unweighted; N= 332,414 weighted) 
were significantly higher for subjects with no insurance ($4,631.7±0), and lower for 
subjects with private ($186.9±1.9) and public insurance ($105.6±4.7). Ambulatory 
care visit (N= 385 unweighted; N= 3,831,325 weighted) OOP expenditures for subjects 
with no insurance ($77.9±14.0) were over 2 times higher than OOP expenditures for 
those privately or publicly insured ($35.0±5.3; $28.2±5.6, respectively). Of those who 
had prescription expenditures (N= 468 unweighted; N= 4,906,191 weighted), patients 
with private and those with no insurance paid similar OOP amounts ($222.1±24.8; 
$224.8±61.4, respectively), while those with public insurance had lower OOP expen-
ditures ($162.5±24.4). CONCLUSIONS: When compared to subjects with private or 
public insurance, those with no insurance had higher OOP expenditures for COPD-
related total, inpatient and ambulatory care services and lower OOP expenditures 
for prescriptions. Increasing the use of appropriate COPD medications among the 
uninsured may result in cost-savings due to reduced hospitalizations.
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information regarding visual status. All-cause hospitalization was ascertained using 
Medicare claims data that were linked to MCBS. The Negative Binomial generalized 
linear model was used to quantify the relationship between VI and hospitalization 
controlling for confounding factors such as age, gender, race, income, education, 
marital status, smoking, body mass index, and chronic conditions. RESULTS: At 
baseline, 23% of beneficiaries had mild VI, and 6% had moderate-to-severe VI. Over 
time, the rate of hospitalization declined for those with mild VI or no VI, but was con-
stant for those with moderate-to-severe VI. The rate of hospitalization was higher 
in beneficiaries with moderate-to- severe VI compared with beneficiaries with no 
VI (Rate Ratio: 1.21, 95% Confidence Interval: 1.06, 1.37), adjusting for potential 
confounding variables. CONCLUSIONS: Moderate-to-severe VI was associated with 
an increased rate of hospitalization among older adults. Our results suggest that 
further research is needed to determine whether treatment of and management of 
visual impairment would be an effective measure to reduce hospitalization.
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OBJECTIVES: Depression is a major cause of increased work absentees and low pro-
ductivity increasing the total healthcare costs. Continuing to work while suffering 
from depression (presenteeism) may actually improve patient condition through col-
league support and reduce healthcare costs, however, there is not enough evidence 
to support this. The objective of this study was to compare health services utiliza-
tion and healthcare costs among employed patients with depression who engage in 
presenteeism and absenteeism. METHODS: A retrospective observational study was 
conducted using the 2011 and 2012 Medical Expenditure Panel Survey (MEPS) data. 
Adult patients (≥ 18 years) with depression were identified using ICD-9 codes (296 and 
311). All depressed patients who were employed throughout the year were assessed 
for presenteeism and absenteeism through survey responses. Logistic regressions 
were used to assess the association between absenteeism/presenteeism and office-
based visits. General linear models were used to assess the total helathcare costs 
among those who engaged in absenteeism and presenteeism. RESULTS: A total of 
1,501 adults with depression were identified. Of those, 66.7% were females. Among 
employed adults with depression, 14.7% engaged in absenteeism, while the others 
engaged in the behavior of presenteeism. After controlling for individual socio-demo-
graphic covariates, clinical comorbidities, and individual perceived health status, 
depressed patients engaging in presenteeism were 65% less likely to have more than 
three office-based visits as compared to patients engaging in absenteeism(OR: 0.349; 
95% CI: 0.235-0.518). Results for the adjusted cost analysis suggest that the behavior of 
presenteeism or absenteeism was not a significant predictor of total healthcare costs 
(p> 0.05). CONCLUSIONS: Compared to absenteeism, presenteeism among employed 
adults with depression is associated with lower health services utilization that can 
potentially be cost-saving in the long run. Employers and the medical community 
should work together for depression management among employees and reduce the 
clinical and economic burden of depression.
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OBJECTIVES: To describe and compare the first hospitalization cost and the 
readmission cost of Acute Myocardial Infarction (AMI) patients at Beijing urban 
area. METHODS: Retrospective data on hospitalization of AMI was selected from 
Beijing urban employees and residents medical insurance database. We randomly 
selected 10% of patients first diagnosed as AMI during January 2012- December 
2012and then followed those patients to September 2013 .1253 patients were 
identified in our study and then 335 patients(26.7%) reoccurred during the obser-
vation period. All information of patient demographic characters, length of stay 
and clinical costs were collected. The descriptive statistics were used. The costs 
of 2013 were converted into 2012 year price with discount rate 3.5%. RESULTS: We 
analyzed the 335 patients with recurrence of AMI,(mean age 66.14±15.04 years; 
82.39% male), among which 100 patients were readmitted to hospital over three 
times. The median followed time was 14.17(IQR11.35-18.37, mean 14.29±4.68, ) 
months. The median hospitalization cost was ¥32,148.42(IQR14303.28-68264.97, 
mean 42,905.99±36,473.35)at the first time, ¥29,189.83(IQR12111.81-64323.44, mean 
41281.34±34909.03)at the second time, and ¥25,386.72(IQR13751.55-49162.27, mean 
34859.87±30294.72) at the third time or more, respectively (p< 0.05) . The median 
length of stay was 11 days (IQR 7-16, mean 13.75±11.34days) in the first hospitali-
zation,11 days (IQR 7-16, mean 13.91±12.67,)in the second hospitalization, and 13 
days (IQR 9-19, mean 16.12±12.97days)in the third hospitalization or more ,respec-
tively. (p< 0.05) CONCLUSIONS: Patients with readmission took a relatively high 
percentage of all AMI hospitalized patients and caused heavy cost. Readmissions 
over three times had lower cost and longer length of hospital stay than the first 
and second hospitalization.
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OBJECTIVES: Chronic kidney disease, overweight and obesity are growing public 
health challenges in the U.S. with large financial implications. To examine health-
care utilization and expenditures among end-stage renal disease population by 
body mass index. METHODS: This was a retrospective cross-sectional study of 225 
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OBJECTIVES: Databases contain large numbers of unselected patients with exten-
sive medical and demographic data spanning many years. Considerable interest 
exists in using large databases to inform economic modelling. Accurate linkage 
and costing are essential to optimising their use in economic evaluation. These 
methods deliver a template to do this. Patients with Irritable bowel syndrome 
(IBS) can be diagnosed and managed entirely in primary care yet around 30% are 
referred to gastroenterology. We use routinely collected electronic records to assess 
how this referral changes total healthcare utilization and its cost. METHODS: 
Within the UK Clinical Practice Research Dataset (CPRD) we identified IBS patients 
with a first gastroenterology visit identified in linked Hospital Episode Statistics 
(HES) in 2008/9. Anyone with organic gastrointestinal disease was excluded. All 
primary care attendances and prescriptions were identified from CPRD and unit 
costs attached. Hospital inpatient stays, outpatient visits and colonoscopies were 
identified in HES. Healthcare Resource Grouping (HRG) was done via the UK NHS 
algorithm and tariff costs applied. Utilization rates and costs (2011/2012 UK £) 
per person year and ratios before and after gastroenterology visit were calculated 
and stratified. RESULTS: In 2008/9, 4811 IBS patients attended gastroenterology 
for the first time. Healthcare utilization increased in all domains before the year 
of referral and decreases after, except prescriptions which continue to increase. 
Mean total annual cost was £2492 three years before referral and £3352 three 
years after (£807 and £821 respectively excluding prescription costs). Costs were 
greatest in older patients, those in lower socioeconomic groups, smokers and 
those diagnosed with IBS less than a year. CONCLUSIONS: Complete primary 
and secondary healthcare utilization and costs can accurately be calculated at 
individual and cohort level using routinely collected data from large databases 
and tariff prices. These data could be used directly in economic modelling from 
the payer’s perspective and to inform policy.
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OBJECTIVES: To analyze the utilization of ERCP-related operations and medical 
supplies as well as their expenses and payment in China BMI inpatients, and 
determine whether the BMI payment policies are appropriate for these inpa-
tients. METHODS: This study used the data from the National Sample Survey 
on Medical Service Utilization of the BMI participants in 2012. Altogether 10,597 
inpatients (2.2% of total) treated by ERCP technologies were extracted from the 
375 thousands total sample inpatients of all over the country. All the actual 
claim data of medical expenses and medical care utilization were collected. 
Descriptive analysis was applied to the data and related BMI payment policies 
were reviewed. RESULTS: 1) About 948 thousands inpatients were treated by ERCP 
technologies in China BMI participants in 2011, 83% of them suffered from the 
digestive system diseases. 2) The average hospitalization medical expenses of 
ERCP inpatients was 11293 RMB (about 1820 USD), among which 45%, 40% and 
15% were for drugs, medical services and medical supplies respectively. 3) The 32 
ERCP-related operations cost more than 414 million RMB (about 67 million USD), 
and Top 5 high-cost operations cost 80.4%. 4) The 16 ERCP-related medical supplies 
cost 194 million RMB (about 31 million USD) and Top 5 cost 58%. The highest price 
of these medical supplies was more than 7500 RMB (about 1210 USD, i.e. enteral 
stent). 5) The average reimbursement rate of ERCP inpatients about 68%, 5 percents 
lower than that of total BMI inpatients. CONCLUSIONS: The ERCP technologies 
were effective new diagnosis and treatment methods used more widely in clinical 
practice at present. The medical expenses of ERCP-related inpatients were higher, 
while their BMI reimbursement level was lower, which meant that their economic 
burden were higher but could get less reimbursement from BMI. The BMI reim-
bursement policies on the ERCP-related operations and medical supplies should 
be adjusted to promote these new medical technologies.
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OBJECTIVES: To estimate colorectal cancer (CRC) -attributable cost in the United 
States by quantifying the direct medical cost of cancer care for CRC patients and 
to study the effects of CRC on direct healthcare costs. METHODS: We used direct 
medical cost data from the household component of the Medical Expenditure Panel 
Surveys (MEPS) of 2008 to 2012that gather healthcare utilization and expenditures 
for the US civilian non-institutionalized population. To estimate CRC-attributable 
cost, patients reporting a past CRC diagnosis were matched with non-cancer 
controls on age, region, poverty level, race, insurance status, and marital status. 
Generalized linear model (GLM) was chosen to model costs. RESULTS: An average 
of 110 persons in each year reported a prior CRC diagnosis.The mean annual direct 
medical cost attributable to CRC was $18,240 in 2008, $18,211 in 2009, $11,192 in 
2010, $11,113 in 2011 and $13,301 in 2012. Applying the findings to SEER estimates of 
population-wide CRC prevalence, CRC attributable costs were $27.59 billion in 2008, 
$25.45 billion in 2009, $14.11 billion in 2010, $13.03 billion in 2011 and $15.08 billion 
in 2012, a trend consistent with the documented overall healthcare cost decline 
following the 2008-09 recession. CONCLUSIONS: Our study revealed a significant 
decline in annual CRC attributable cost in 2010. Our findings may be confounded by 
5-plus year survivors who may no longer qualify as “cancer” patients, and by stage 
at diagnosis among the study sample. Localized disease is associated with a 90% 
5-year survival rate. Study limitations include: a) a lack of consistent data on time 
since cancer diagnosis which is relevant to cancer care cost computations, and, b) 
lack of data on stage at diagnosis. With about 130,000 new cases each year, additional 
research is warranted to develop accurate cost estimates.
OBJECTIVES: An increase of financial risk in healthcare is associated with many issues 
such as poor quality of hospital care, bureaucratic management methods used in state 
hospitals, low remuneration of health professionals, financing based on not real costs 
of services and almost absence of procurement activities in hospitals. The aim of the 
study was to estimate outpatient and inpatient care costs in provincial general hos-
pitals. METHODS: We were using top down cost estimation method. Total eight pro-
vincial hospitals participated in the study. RESULTS: Generally, 51 percent of the total 
costs was spent for inpatient medical care, 11 percent was spent on outpatient care, 
5 percent was spent on emergency care, 18 percent was spent for additional services 
and 18 percent were for management costs. In Umnugobi provincial general hospital 
there were 455 outpatients per employee, whereas 200 outpatients per employee were 
in Dornod provincial general hospital. There were 34 and 17 inpatients per employee 
at Khovd provincial general hospital and Tov provincial general hospital respectively 
whereas the average was 27. Day surgery costs were the highest, 248.583 MNT, and 
the lowest costs were for eye outpatient, 7270 MNT. The highest costs were average 
emergency care cost, 2 028 966 MNT, and tuberculosis treatment costs, 1 895 340 MNT. 
Average cost of inpatient care was 574 236 MNT. CONCLUSIONS: In average only 11 
percent of hospital budget was spent on emergency care, which was insufficient. 
Umnugobi provincial general hospital employees had by 44.3 percent higher work-
load compared to Dornod provincial general hospital employees. Khovd Diagnostic 
and Treatment Regional Centre Hospital’s inpatient workload per employee was 50 
percent higher compare to Tov provincial general hospital.
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OBJECTIVES: To describe and compare the first hospitalization cost and the readmis-
sion cost of Ischemic Stroke (IS) patients at Beijing urban area. METHODS: Retrospective 
data on hospitalization of IS was selected from Beijing urban employees and residents 
medical insurance database. We randomly selected 10% of patients first diagnosed as 
IS during January 2012- December, 2012and then followed those patients to September 
2013. 4504 patients were identified in our study and then 2371 patients reoccurred dur-
ing the observation period. All information of patient demographic characters, length 
of stay and clinical costs were collected. The descriptive statistics were used in the 
data analysis. The costs of 2013 were converted into 2012 year price with discount 
rate 3.5%. RESULTS: We analyzed the 2371 patients with recurrence of IS,(mean age 
69.482±13.68 years; 64.78% male), among which 1448 patients(61%) were readmitted 
to hospital over three times. The median followed time was 15.6 months ( IQR12.37-
18.6, mean15.86±3.69). The median hospitalization cost was ￥13794.16 (IQR9659.26-
20529.71, mean 19933.24±23253.07)at the first time, ￥13710 (IQR9580.68-20907.06, mean 
19682.76±23163.26) at the second time, and ￥13977.03 (IQR 9831.29- 21631.75, mean 
19893.81±21848.2)at the third time or more, respectively(P< 0.05). The median length 
of stay was 15 days (IQR 11-21, mean 17.89±12.73) in the first hospitalization, 15 days 
(IQR 11-22, mean 18.18±12.64) in the second hospitalization and 15 days(IQR11-23,mean 
18.82±13.15) in the third hospitalization or more, respectively(p< 0.05). CONCLUSION
S: Patients with readmission took a high percentage of all hospitalized IS patients and 
caused heavy hospitalization cost. Hospitalizations of the second time had shorter 
length of stay than those at the first hospitalization and the third or more, total hospi-
talization cost of different admissions showed no significant difference.
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OBJECTIVES: Hepatitis C (HCV) is a curable disease that affects roughly 242,000 
Canadians and 24,000 Albertans. Without treatment, those infected may develop 
cirrhosis, hepatocellular cancer (HCC) and irreversible decompensated cirrhosis 
(DCC). This study examines the current Alberta “market” for HCV-related services. 
Little is currently known about the segmentation of providers within this market 
or the degree to which these segments of providers are integrated into the overall 
HCV services market. The expenditure required to fund various HCV service seg-
ments is also unknown. METHODS: We conducted a costing analysis to estimate 
the expenditure required to fund the current HCV services market and its various 
segments in Alberta. In order to conduct this analysis, it was necessary to describe 
the current market associated with different segments of care for HCV. Information 
was obtained from the literature and through consultation with health care profes-
sionals involved in providing HCV-related services. RESULTS: Six segments were 
identified within the overall HCV service market. These included prevention, screen-
ing, early treatment, later treatment for advanced liver disease (including liver trans-
plant), and finally end stage liver disease (ESLD). The estimated cost for HCV-related 
services overall was $47 million (CAD$) per year. Late and ESLD were associated 
with a cumulative cost of $17.8 million ($8.5 million for late stage and $9.3 million 
for ESLD). Treatment with antivirals (i.e., early segment) was associated with $15 
million in costs. CONCLUSIONS: Costs in Alberta will likely increase in the future 
because of the current lack of integration across HCV service provider segments 
such as screening and early treatment referral. System capacity limitations for 
early treatment and liver transplants will also contribute to future increases in cost.
PHS135
coSt of Primary and Secondary HealtHcare utilization for PatientS 
witH irritable bowel Syndrome calculated uSing routinely 
collected electronic recordS to aSSeSS tHe imPact of Secondary 
care referral
Canavan C., Card T., West J.
University of Nottingham, Nottingham, UK
